Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells

about

Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells

Item

http://www.wikidata.org/entity/Q58790703

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@en

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@nl

type

Item

label

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@en

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@nl

prefLabel

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@en

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@nl

P1476

Characterisation of the Morpho ...... ant Renal Cell Carcinoma Cells

@en

P2093

Christudas Morais

http://www.w3.org/2001/XMLSchema#string

David A Vesey

http://www.w3.org/2001/XMLSchema#string

Gobe C Glenda

http://www.w3.org/2001/XMLSchema#string

Hossam Kamli

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

P2860

Combination therapy for renal cell cancer: what are possible options?

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15586/JKCVHL.2018.106

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30109169

http://www.w3.org/2001/XMLSchema#string

P932

6088203

http://www.w3.org/2001/XMLSchema#string